Tempus AI’s (TEM) Buy Rating Reaffirmed at BTIG Research

Tempus AI (NASDAQ:TEM)‘s stock had its “buy” rating reissued by investment analysts at BTIG Research in a report released on Monday, Benzinga reports. They currently have a $80.00 price target on the stock. BTIG Research‘s price objective would suggest a potential upside of 20.19% from the stock’s previous close.

A number of other research firms also recently commented on TEM. Raymond James Financial set a $80.00 price objective on shares of Tempus AI in a report on Wednesday, September 2nd. Piper Sandler raised Tempus AI from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $56.00 to $76.00 in a research note on Tuesday, September 1st. Canaccord Genuity Group lifted their price objective on shares of Tempus AI from $80.00 to $95.00 and gave the company a “buy” rating in a report on Monday, October 12th. The Goldman Sachs Group started coverage on shares of Tempus AI in a report on Monday, September 21st. They issued a “neutral” rating and a $75.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on shares of Tempus AI in a report on Wednesday, September 2nd. They issued an “overweight” rating and a $80.00 price objective for the company. Eleven equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $72.47.

Tempus AI Price Performance

TEM traded down $1.05 during trading on Monday, hitting $66.56. The company’s stock had a trading volume of 1,840,459 shares, compared to its average volume of 6,169,494. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The firm has a market capitalization of $12.01 billion, a price-to-earnings ratio of -46.15 and a beta of 3.54. Tempus AI has a twelve month low of $40.77 and a twelve month high of $93.38. The business’s fifty day simple moving average is $69.24 and its 200 day simple moving average is $57.26.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The business had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company’s revenue was up 21.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.22) earnings per share. On average, equities research analysts forecast that Tempus AI will post -1.43 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Andrew Polovin sold 2,951 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total transaction of $221,325.00. Following the completion of the sale, the executive vice president owned 135,189 shares in the company, valued at $10,139,175. The trade was a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric P. Lefkofsky sold 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $77.47, for a total value of $19,367,500.00. Following the sale, the chief executive officer owned 100,000 shares of the company’s stock, valued at approximately $7,747,000. The trade was a 71.43% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,280,965 shares of company stock worth $80,397,564. 24.26% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Tempus AI

Several institutional investors have recently added to or reduced their stakes in the business. Guardian Partners Inc. grew its stake in Tempus AI by 8.3% in the third quarter. Guardian Partners Inc. now owns 2,600 shares of the company’s stock worth $213,000 after purchasing an additional 200 shares in the last quarter. V Square Quantitative Management LLC acquired a new stake in Tempus AI in the 3rd quarter valued at approximately $27,000. Cyndeo Wealth Partners LLC increased its position in Tempus AI by 6.7% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 6,412 shares of the company’s stock valued at $525,000 after acquiring an additional 400 shares during the period. Arkadios Wealth Advisors raised its position in shares of Tempus AI by 9.6% during the 1st quarter. Arkadios Wealth Advisors now owns 4,963 shares of the company’s stock worth $224,000 after buying an additional 435 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Tempus AI by 54.3% in the third quarter. GAMMA Investing LLC now owns 1,239 shares of the company’s stock valued at $101,000 after buying an additional 436 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.